ZA200709608B - Histone deacetylase inhibitors - Google Patents
Histone deacetylase inhibitorsInfo
- Publication number
- ZA200709608B ZA200709608B ZA200709608A ZA200709608A ZA200709608B ZA 200709608 B ZA200709608 B ZA 200709608B ZA 200709608 A ZA200709608 A ZA 200709608A ZA 200709608 A ZA200709608 A ZA 200709608A ZA 200709608 B ZA200709608 B ZA 200709608B
- Authority
- ZA
- South Africa
- Prior art keywords
- histone deacetylase
- deacetylase inhibitors
- linker1
- linker2
- linked
- Prior art date
Links
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title abstract 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 title abstract 2
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000165 tricyclic carbocycle group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0510204.1A GB0510204D0 (en) | 2005-05-19 | 2005-05-19 | Enzyme inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200709608B true ZA200709608B (en) | 2008-12-31 |
Family
ID=34708420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200709608A ZA200709608B (en) | 2005-05-19 | 2007-11-07 | Histone deacetylase inhibitors |
Country Status (20)
Country | Link |
---|---|
US (1) | US7932246B2 (da) |
EP (1) | EP1881977B1 (da) |
JP (1) | JP4954200B2 (da) |
KR (1) | KR20080016539A (da) |
CN (1) | CN101163696B (da) |
AT (1) | ATE494283T1 (da) |
AU (1) | AU2006248788B2 (da) |
BR (1) | BRPI0611522B1 (da) |
CA (1) | CA2605050C (da) |
DE (1) | DE602006019410D1 (da) |
DK (1) | DK1881977T3 (da) |
ES (1) | ES2358604T3 (da) |
GB (2) | GB0510204D0 (da) |
IL (1) | IL186362A (da) |
MX (1) | MX2007013066A (da) |
NZ (1) | NZ562519A (da) |
PL (1) | PL1881977T3 (da) |
PT (1) | PT1881977E (da) |
WO (1) | WO2006123121A1 (da) |
ZA (1) | ZA200709608B (da) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2059505A2 (en) * | 2006-09-04 | 2009-05-20 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
CN101573333B (zh) | 2006-10-28 | 2013-06-12 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
CA2668070A1 (en) | 2006-10-30 | 2008-05-08 | Chroma Therapeutics Ltd. | Hydroxamates as inhibitors of histone deacetylase |
AU2007333799A1 (en) * | 2006-12-15 | 2008-06-26 | Novartis Ag | Heterocycle compounds and methods of use thereof |
CN101918389A (zh) * | 2007-11-02 | 2010-12-15 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
EP2231596A4 (en) | 2007-12-14 | 2012-06-06 | Univ Georgetown | INHIBITORS OF HISTONATE ACETYLASE |
GB0803747D0 (en) | 2008-02-29 | 2008-04-09 | Martin | Enzyme and receptor modulation |
CA2716932C (en) | 2008-03-27 | 2017-07-04 | Eddy Jean Edgard Freyne | Aza-bicyclohexyl substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
EP2110377A1 (en) * | 2008-04-15 | 2009-10-21 | DAC S.r.l. | Spirocyclic derivatives as histone deacetylase inhibitors |
WO2009137503A1 (en) * | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Hdac inhibitors and uses thereof |
WO2009137499A1 (en) * | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Inhibitors of histone deacetylase |
JP2011520891A (ja) * | 2008-05-16 | 2011-07-21 | チップスクリーン バイオサイエンシーズ エルティーディー. | 強力かつ選択的なヒストン脱アセチル化酵素阻害剤としての6−アミノニコチンアミド誘導体 |
FR2945533B1 (fr) * | 2009-05-12 | 2011-05-27 | Sanofi Aventis | Derives de cyclopenta°c!pyrrolyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
JP5848251B2 (ja) | 2009-10-23 | 2016-01-27 | ヤンセン ファーマシューティカ エヌ.ベー. | オレキシン受容体調節因子としての縮合複素環式化合物 |
EP2491034B1 (en) | 2009-10-23 | 2013-12-18 | Janssen Pharmaceutica, N.V. | Fused heterocyclic compounds as orexin receptor modulators |
JP5759470B2 (ja) | 2009-10-23 | 2015-08-05 | ヤンセン ファーマシューティカ エヌ.ベー. | オレキシン受容体調節因子としての二置換オクタヒドロピロロ[3,4−c]ピロール |
US20110245154A1 (en) | 2010-03-11 | 2011-10-06 | Hemaquest Pharmaceuticals, Inc. | Methods and Compositions for Treating Viral or Virally-Induced Conditions |
WO2012042539A2 (en) | 2010-09-28 | 2012-04-05 | Panacea Biotec Ltd | Novel bicyclic compounds |
CA2818125A1 (en) * | 2010-11-16 | 2012-05-24 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
WO2012145581A1 (en) | 2011-04-20 | 2012-10-26 | Janssen Pharmaceutica Nv | Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
GB201211310D0 (en) | 2012-06-26 | 2012-08-08 | Chroma Therapeutics Ltd | CSF-1R kinase inhibitors |
WO2014028829A1 (en) * | 2012-08-16 | 2014-02-20 | The Scripps Research Institute | Novel kappa opioid ligands |
PL3222616T3 (pl) | 2012-10-17 | 2019-12-31 | Macrophage Pharma Limited | N-[2-{4-[6-amino-5-(2,4-difluorobenzoilo)-2-oksopirydyn-1(2h)-ylo]-3,5-difluorofenylo}etylo)-L-alaninian tert-butylu lub jego sól, hydrat lub solwat |
JP6626437B2 (ja) | 2013-10-08 | 2019-12-25 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | ヒストンデアセチラーゼ阻害剤とHer2阻害剤またはPI3K阻害剤のいずれかの組み合わせ |
ES2862126T3 (es) | 2013-10-10 | 2021-10-07 | Acetylon Pharmaceuticals Inc | Compuestos de pirimidín-hidroxiamida como inhibidores de histona desacetilasa |
EP4137135B1 (en) | 2013-10-24 | 2024-06-05 | Mayo Foundation for Medical Education and Research | Treatment of polycystic diseases with an hdac6 inhibitor |
CR20160308A (es) | 2013-12-03 | 2016-11-08 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores |
US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
KR20170012404A (ko) * | 2014-06-02 | 2017-02-02 | 씨에이치디아이 파운데이션, 인코포레이티드 | 히스톤 데아세틸라제 억제제 및 그것의 조성물 및 사용 방법 |
CN107205988A (zh) | 2014-07-07 | 2017-09-26 | 埃斯泰隆制药公司 | 利用组蛋白脱乙酰酶抑制剂治疗白血病 |
WO2016086060A1 (en) | 2014-11-26 | 2016-06-02 | The J. David Gladstone Institutes | Methods for treating a cytomegalovirus infection |
AU2015356779A1 (en) | 2014-12-05 | 2017-07-13 | University of Modena and Reggio Emilia | Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma |
MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
TWI698436B (zh) | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶 |
EP3253765A1 (en) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors |
EP3253759A1 (en) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors |
EP3253738A1 (en) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
KR20170124602A (ko) | 2015-03-13 | 2017-11-10 | 포르마 세라퓨틱스 인크. | Hdac8 억제제로서의 알파-신나미드 화합물 및 조성물 |
US10272084B2 (en) | 2015-06-01 | 2019-04-30 | Regenacy Pharmaceuticals, Llc | Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy |
KR102559922B1 (ko) | 2016-03-10 | 2023-07-25 | 얀센 파마슈티카 엔.브이. | 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법 |
US11813261B2 (en) | 2016-04-19 | 2023-11-14 | Acetylon Pharmaceuticals, Inc. | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia |
CN109803661A (zh) * | 2016-07-15 | 2019-05-24 | 维拉克塔治疗公司 | 用于免疫疗法的组蛋白脱乙酰酶抑制剂 |
RS60209B1 (sr) | 2017-03-20 | 2020-06-30 | Forma Therapeutics Inc | Kompozicije pirolopirola kao aktivatori piruvat kinaze (pkr) |
GB201713975D0 (en) | 2017-08-31 | 2017-10-18 | Macrophage Pharma Ltd | Medical use |
EP3686196B1 (en) * | 2017-09-20 | 2024-06-12 | Hangzhou Innogate Pharma Co., Ltd. | Polycyclic compound acting as ido inhibitor and/or ido-hdac dual inhibitor |
EP3697759A4 (en) | 2017-10-20 | 2021-05-12 | Vanderbilt University | MUSCARINIAN ACETYLCHOLINE RECEPTOR ANTAGONISTS M4 |
JP2021503443A (ja) | 2017-10-31 | 2021-02-12 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体m4のアンタゴニスト |
WO2019152809A1 (en) | 2018-02-02 | 2019-08-08 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
US20220031671A1 (en) | 2018-09-19 | 2022-02-03 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
US20220154282A1 (en) | 2019-03-12 | 2022-05-19 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
CN109912576B (zh) * | 2019-03-20 | 2021-11-19 | 华东理工大学 | 环状或螺环二胺类嘧啶-异羟肟酸及其用途 |
CN109810108B (zh) * | 2019-03-20 | 2021-08-06 | 华东理工大学 | 2,8-二氮杂-螺-[4,5]-癸烷类嘧啶-异羟肟酸化合物及其用途 |
CN114502540A (zh) | 2019-05-31 | 2022-05-13 | 医肯纳肿瘤学公司 | Tead抑制剂和其用途 |
KR20220034736A (ko) | 2019-05-31 | 2022-03-18 | 비락타 서브시디어리 인크. | 히스톤 데아세틸라제 억제제를 사용하여 바이러스 관련 암을 치료하는 방법 |
JP2022534426A (ja) | 2019-05-31 | 2022-07-29 | イケナ オンコロジー, インコーポレイテッド | Tead阻害剤およびその使用 |
JP2022552642A (ja) * | 2019-10-07 | 2022-12-19 | ヴィラクタ サブシディアリー,インク. | 副作用が軽減されたhdac治療の調剤 |
MX2022006741A (es) | 2019-12-05 | 2022-06-14 | Viracta Subsidiary Inc | Formas de estado solido del inhibidor de hdac. |
KR20230097098A (ko) | 2020-10-28 | 2023-06-30 | 비락타 서브시디어리 인크. | Hdac 억제제 고체 상태 형태 |
WO2022266162A1 (en) | 2021-06-16 | 2022-12-22 | Celgene Corporation | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
CN115417877B (zh) * | 2022-09-20 | 2024-05-14 | 杭州师范大学 | 组蛋白去乙酰化酶抑制剂及其制备和在制备抗癌症药物上的应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7205304B2 (en) * | 2002-03-13 | 2007-04-17 | Janssen Pharmaceutica N.V. | Sulfonyl-Derivatives as novel inhibitors of histone deacetylase |
PL213783B1 (pl) * | 2002-03-13 | 2013-05-31 | Janssen Pharmaceutica Nv | Podstawiona pochodna piperydyny lub piperazyny, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna |
ATE396971T1 (de) * | 2002-03-13 | 2008-06-15 | Janssen Pharmaceutica Nv | Sulfonylaminoderivate als neue inhibitoren von histondeacetylase |
US7247092B2 (en) | 2003-06-09 | 2007-07-24 | Igt | Gaming device having a multiplier poker game |
EP1644323B1 (en) | 2003-07-07 | 2015-03-18 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
EP1663201A4 (en) | 2003-07-15 | 2009-10-28 | Korea Res Inst Of Bioscience | USE OF NEW 2-OXO-HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL PREPARATIONS CONTAINING THEREOF |
US20060270730A1 (en) | 2003-08-07 | 2006-11-30 | Andreas Katopodis | Histone deacetylase inhibitors as immunosuppressants |
DE602004004665T2 (de) | 2003-08-20 | 2008-01-03 | Pharmacyclics, Inc., Sunnyvale | Acetylenderivate als inhibitoren von histondeacetylase |
DK1673349T3 (da) | 2003-09-22 | 2010-10-25 | S Bio Pte Ltd | Benzimidazolderivater: fremstilling og farmaceutiske anvendelser |
WO2005030705A1 (en) | 2003-09-24 | 2005-04-07 | Methylgene, Inc. | Inhibitors of histone deacetylase |
-
2005
- 2005-05-19 GB GBGB0510204.1A patent/GB0510204D0/en not_active Ceased
-
2006
- 2006-05-15 AU AU2006248788A patent/AU2006248788B2/en not_active Ceased
- 2006-05-15 BR BRPI0611522-5A patent/BRPI0611522B1/pt active IP Right Grant
- 2006-05-15 JP JP2008511780A patent/JP4954200B2/ja active Active
- 2006-05-15 DE DE602006019410T patent/DE602006019410D1/de active Active
- 2006-05-15 GB GB0618717A patent/GB2429707B/en not_active Expired - Fee Related
- 2006-05-15 AT AT06727119T patent/ATE494283T1/de active
- 2006-05-15 KR KR1020077023574A patent/KR20080016539A/ko not_active Application Discontinuation
- 2006-05-15 US US11/918,237 patent/US7932246B2/en active Active
- 2006-05-15 ES ES06727119T patent/ES2358604T3/es active Active
- 2006-05-15 WO PCT/GB2006/001779 patent/WO2006123121A1/en active Application Filing
- 2006-05-15 PT PT06727119T patent/PT1881977E/pt unknown
- 2006-05-15 CA CA2605050A patent/CA2605050C/en active Active
- 2006-05-15 CN CN2006800136471A patent/CN101163696B/zh active Active
- 2006-05-15 PL PL06727119T patent/PL1881977T3/pl unknown
- 2006-05-15 MX MX2007013066A patent/MX2007013066A/es active IP Right Grant
- 2006-05-15 DK DK06727119.7T patent/DK1881977T3/da active
- 2006-05-15 NZ NZ562519A patent/NZ562519A/en unknown
- 2006-05-15 EP EP06727119A patent/EP1881977B1/en not_active Not-in-force
-
2007
- 2007-10-07 IL IL186362A patent/IL186362A/en active IP Right Grant
- 2007-11-07 ZA ZA200709608A patent/ZA200709608B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP2008540623A (ja) | 2008-11-20 |
BRPI0611522A2 (pt) | 2010-09-21 |
DE602006019410D1 (de) | 2011-02-17 |
AU2006248788B2 (en) | 2011-05-26 |
US20100152155A1 (en) | 2010-06-17 |
WO2006123121A1 (en) | 2006-11-23 |
ES2358604T3 (es) | 2011-05-12 |
BRPI0611522B1 (pt) | 2021-08-03 |
EP1881977A1 (en) | 2008-01-30 |
GB0618717D0 (en) | 2006-11-01 |
AU2006248788A1 (en) | 2006-11-23 |
CA2605050A1 (en) | 2006-11-23 |
GB2429707A (en) | 2007-03-07 |
MX2007013066A (es) | 2008-01-11 |
US7932246B2 (en) | 2011-04-26 |
ATE494283T1 (de) | 2011-01-15 |
IL186362A (en) | 2012-01-31 |
NZ562519A (en) | 2010-11-26 |
CN101163696A (zh) | 2008-04-16 |
DK1881977T3 (da) | 2011-04-04 |
GB2429707B (en) | 2007-06-13 |
KR20080016539A (ko) | 2008-02-21 |
IL186362A0 (en) | 2008-01-20 |
CN101163696B (zh) | 2011-09-14 |
PT1881977E (pt) | 2011-04-11 |
PL1881977T3 (pl) | 2011-07-29 |
GB0510204D0 (en) | 2005-06-22 |
EP1881977B1 (en) | 2011-01-05 |
JP4954200B2 (ja) | 2012-06-13 |
CA2605050C (en) | 2014-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL186362A0 (en) | Histone deacetylase inhibitors | |
MX2009004279A (es) | Hidroxamatos como inhibidores de histona desacetilasa. | |
NO20061157L (no) | 4-pyramidonderivater og deres anvendelse som peptidylpeptidmeinbibitorer | |
SG145700A1 (en) | Pyridyl derivatives and their use as therapeutic agents | |
HK1125359A1 (en) | N-sulphonylpyrroles and their use as histone deacetylase inhibitors n- | |
NO20044557L (no) | Inhibitorer av histon deacetylase | |
ATE424395T1 (de) | Aminoderivate als histone-deacetylase-inhibitoren | |
IL164511A0 (en) | Heterocyclic compounds | |
MX2008002293A (es) | Uso novedoso de compuestos peptidicos para tratar dolor muscular. | |
SG145701A1 (en) | Piperazine derivatives and their use as therapeutic agents | |
DE60143520D1 (de) | Inhibitoren der histon-deacetylase | |
UA88166C2 (ru) | Применение пептидных соединений для лечения эссенцильного дрожания и других синдромов дрожания | |
MY138059A (en) | Use of ikb-kinase inhibitors in pain therapy | |
ATE439355T1 (de) | 2 aminocarbonyl-substituierte piperazin- oder diaza-cyclische verbindungen als apoptose-protein-inhibitor (iap)-modulatoren | |
TR200401793T4 (tr) | Perindopril tuzu ve bunu içeren farmasötik bileşimler. | |
DE60112306D1 (de) | Kondensierte pyrazindionderivate als pde5 inhibitore | |
AR044452A1 (es) | Combinacion de un antagonista del receptor p2x7 y un inhibidor del factor de necrosis tumoral alfa | |
MXPA05009282A (es) | Derivados de anilina sustituidos. | |
TW200738244A (en) | 20-Alkyl, gemini vitamin D3 compounds and methods of use thereof | |
DE60305053D1 (de) | Pyrimidinderivate als selektive cox-2-inhibitoren | |
DK0984936T3 (da) | Cyanoguanidiner som celleproliferationsinhibitorer | |
ATE337320T1 (de) | Indolderivate als pde5-inhibitoren | |
EA200501557A1 (ru) | Новый способ синтеза (2s)-индолин-2-карбоновой кислоты и использование в синтезе периндоприла | |
DE60213798D1 (de) | Carbolinderivate als pdev inhibitoren | |
SG171472A1 (en) | Substituted aniline derivatives |